The NK-1 antagonist, Fosaprepitant, versus Ondansetron for prevention of postoperative nausea and vomiting

The NK-1 antagonist, Fosaprepitant, versus Ondansetron for prevention of postoperative nausea and vomiting - The NK-1 antagonist, Fosaprepitant, versus Ondansetron for prevention of postoperative nausea and vomiting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008621

Enrollment

200

Registered

2012-08-06

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

On the day of surgery, Fosaprepitant group takes Fosaprepitant 150mg:iv 1 hours before anticipated induction of anesthesia. On the day of surgery, Ondansetron group takes Ondansetron 4mg:iv 1 hours b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients meet the criteria of the American Society of Anesthesiologists(ASA) physical status of 1-2.

Exclusion criteria

Exclusion criteria: Patiens are excluded the criteria of the American Society of Anesthesiologists(ASA) physical status of over 3 and taked antiemetic drugs. Further, excluded contraindication of Fosaprepitant and Ondansetron.

Design outcomes

Primary

Measure	Time frame
frequency of the postoperative nausea and vomiting	—

Countries

Japan

Contacts

Public ContactNami Kakuta

Tokushima University Hospital Anesthesiology

kakuta.nami@tokusima-u.ac.jp088-633-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026